EP1293201A2 - Utilisation de composés d'aminoadamantane en tant qu'immunorégulateurs - Google Patents

Utilisation de composés d'aminoadamantane en tant qu'immunorégulateurs Download PDF

Info

Publication number
EP1293201A2
EP1293201A2 EP02026914A EP02026914A EP1293201A2 EP 1293201 A2 EP1293201 A2 EP 1293201A2 EP 02026914 A EP02026914 A EP 02026914A EP 02026914 A EP02026914 A EP 02026914A EP 1293201 A2 EP1293201 A2 EP 1293201A2
Authority
EP
European Patent Office
Prior art keywords
adamantane
neutrophils
amino
aminoadamantane
ring members
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02026914A
Other languages
German (de)
English (en)
Other versions
EP1293201A3 (fr
Inventor
Erich F. Elstner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merz Pharma GmbH and Co KGaA
Original Assignee
Merz Pharma GmbH and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma GmbH and Co KGaA filed Critical Merz Pharma GmbH and Co KGaA
Publication of EP1293201A2 publication Critical patent/EP1293201A2/fr
Publication of EP1293201A3 publication Critical patent/EP1293201A3/fr
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Definitions

  • the invention relates to the use of aminoadamantane compounds as immunoregulators, especially for the regulation and modulation of already activated neutrophils.
  • Neutrophils a subclass of leukocytes, are involved in immune defense and other reactions in the blood vessel system and bordering tissues (Roitt, I.M, Leitfaden der Immunologie, Steinkopf-Verlag Darmstadt, 2nd edition, 1984).
  • Neutrophils can be activated by exogenous substances, such as for example cell wall components (a commercially obtainable product is "Zymosan”). In connection with this, reactive oxygen species are formed in the so-called respiratory burst.
  • exogenous substances such as for example cell wall components (a commercially obtainable product is "Zymosan”).
  • reactive oxygen species are formed in the so-called respiratory burst.
  • FIG. 1 describes a simplified scheme of neutrophil stimulation: After binding of a ligand (for example, Zymosan A) to a specific receptor on the neutrophil membrane, guanosine triphosphate (GTP) is activated, which in turn activates the phosphatidyl-inositol-4,5-biphosphate (PIP 2 )-specific phospholipase C (PLC). PLC catalyses the hydrolysis of PIP 2 to inositol-1,4,5-triphosphate (IP 3 ) and diacylglycerol (DG). IP 3 stimulates the release of Ca 2+ ions from intracellular stores.
  • GTP guanosine triphosphate
  • PIP 2 phosphatidyl-inositol-4,5-biphosphate
  • PLC phosphatidyl-inositol-4,5-biphosphate
  • PLC phosphatidyl-inositol-4,5-biphosphate
  • PLC phosphatidyl
  • NADPH oxidase catalyses in turn the reaction: 2 O 2 + NADPH ⁇ 2 O 2 - + NADP + + H + wherein the reactive oxygen species O 2 - results.
  • neutrophil activity can be too low or insufficient for a successful immune defense with a general immune deficiency such as for example with AIDS.
  • the neutrophil activity should be either increased or decreased depending on the indication, i.e. should be controllable at will.
  • the object of the present invention is to make available an agent for the regulation and/or modulation of the activity of neutrophils.
  • R 1 , R 2 , R 3 and R 4 are selected independently from each other from -NR 5 R 6 , -NR 5 R 6 R 7 + , hydrogen, aryl or heteroaryl with up to 7 ring members, C 1 -C 20 -alkyl, C 1 -C 20 -alkenyl and C 1 -C 20 -alkinyl, wherein the alkyl, alkenyl and alkinyl residues can be branched, unbranched or cyclized and optionally substituted with halogen, aryl or heteroaryl with up to 7 ring members, with the proviso that at least one of the residues R 1 , R 2 , R 3 and R 4 are represented by -NR 5 R 6 or -NR 5 R 6 R 7 ; and R 5 , R 6 and R 7 are selected independently from each other from hydrogen, aryl or heteroaryl with up to 7 ring members, C
  • Aminoadamantane compounds of this type are known.
  • 1-aminoadamantanes are described in DE 22 19 256, DE 28 56 393, DE 22 32 735, US 3 450 761 or 4 122 193.
  • the production of compounds of formula (I) generally occurs by known methods, such as for example the alkylation of halogen adamantanes. Subsequent further halogenation and alkylation produce the individual di- and/or tri- substituted adamantanes.
  • EP 392 059 whose teaching is explicitly incorporated herein by reference, is referred to for the production of aminoadamantanes.
  • Aminoadamantane compounds have also already been used for pharmaceutical purposes.
  • EP 392 059 discloses the use of 1-aminoadamantane compounds for the treatment of Alzheimer's disease or brain cell damage as a result of cerebral ischemia.
  • US 3 450 761 describes aminoadamantanes with anti-viral activity.
  • Whether the activity of neutrophils is increased or partially or entirely inhibited depends on the concentration of the aminoadamantane compound used. Thus, concentrations from 10 -6 to 10 -5 M have an activity increasing effect. A concentration of about 5 ⁇ 10 -6 M has proven especially effective for increasing neutrophil activity - a concentration which can be well achieved in vivo in blood plasma. In contrast, an inhibition of activity results with an increase of the aminoadamantane concentration. A concentration suitable for this purpose is 10 -4 to 10 -3 M.
  • the invention comprises adamantane compounds substituted with one or with more amino groups, wherein monoaminoadamantanes are preferred.
  • suitable compounds of formula (I) are those wherein R 1 represents an amino group such as for example 1-amino-3-ethyl-5,7-dimethyl-adamantane; as well as compounds wherein R 1 represents an amino group and R 3 and R 4 represent a hydrogen atom, such as for example 1-amino-3-cyclohexyl-adamantane or 1-amino-3-ethyl-adamantane.
  • Preferred adamantane compounds are 1-amino-3,5-dimethyl-adamantane, 1-amino-3,5-diethyl-adamantine and the N-substituted compounds 1-N-methylamino-3,5-dimethyl-adamantane and the compound 1-N-ethylamino-3,5-dimethyl-adamantane.
  • Particularly preferred is 1-amino-3,5-dimethyl-adamantane referred to as memantine (INN, Akatinol Memantine®).
  • memantine INN, Akatinol Memantine®
  • Görtelmeyer, R., et al describe the treatment of Demens syndrome with memantine in Spectrum of Neurorehabilitation, W. Zuckhedt Publishers, Kunststoff, 1993, 50ff.
  • the aminoadamantane compounds according to the invention only have a regulating effect on neutrophils which are pre-activated or have been stimulated by special activators.
  • Natural substances such as Zymosan, N-formyl-Met-Leu-Phe (N-FLMP) or A 23187 (a Ca antagonist) are known as activators. These substances can be used if one intends to specifically and more intensely activate neutrophils in vitro, but also in vivo. By this, it is possible to detect neutrophils in a sample, for example in a sample of body fluid, especially a blood sample, even when only few neutrophils are present or when their activity is very weak.
  • the activator can be present in combination with the aminoadamantane compound: The degree of activation of the neutrophils stimulated by the activator is intensified by the simultaneous addition of aminoadamantane compound.
  • a further field of application is the improvement of immune defense in persons with various forms of immune deficiencies, especially AIDS patients.
  • a pharmaceutical composition can be administered which comprises a aminoadamantane compound according to the invention, optionally in combination with a neutrophil activator.
  • CGD agranulomatosis
  • Wegener's granulomatosis and/or glycogen storage diseases is possible.
  • the neutrophils can also be activated as a consequence of a natural immune response of the organism as a reaction to diverse immunogens and trigger allergic reactions, inflammations and rheumatic symptoms due to overreaction.
  • the neutrophil activity can be attenuated with suitably increased aminoadamantane concentrations and the patient can be given relief.
  • Internal and external inflammation conditions for example in the knee, hip or jaw and also autoimmune diseases can be particularly combated effectively with aminoadamantane containing medicine.
  • parasitic diseases such as Leishmannia.
  • the invention also comprises combinations of the aminoadamantane compounds according to the invention as well as pharmaceutically acceptable salts, especially acid addition salts; for example, hydrochlorides, hydrobromides, sulfates, acetates, succinates, tartrates or addition compounds with fumaric, maleic, citric or phosphoric acid are to be named here.
  • pharmaceutical compositions can additionally contain a neutrophil activator depending on the range of indications. Customary pharmaceutically acceptable carriers and adjuvants are used for the formulation.
  • the following example illustrates the dependence of the activity increasing or inhibiting effect of aminoadamantane derivatives by means of the special compound, memantine.
  • chemiluminescence measurement The determination of activity of stimulated neutrophils at various memantine concentrations was conducted by chemiluminescence measurement. Activated neutrophils form reactive oxygen species in the respiratory burst which are detectable as very weak chemiluminescence - so-called low-level or ultra-weak chemiluminescence.
  • luminol is added as a sensitizer (indicator dependent chemiluminescence).
  • Luminol is a cyclic hydrazide which can be oxidized to diazoquinone through reactive oxygen species. By a nucleophil attack of a hydrogen peroxide anion, this diazoquinone is further converted to a-hydroxyhydroperoxide which disintegrates into aminophtalate under light emission.
  • Analogous reaction batches can be produced with further adamantane compounds.
  • Measurement was conducted with very sensitive, low-noise photomultipliers which convert photons on a photocathode into primary electrons and then multiply amplify these to an electrical impulse signal.
  • This reaction does not occur by stimulating with toxic P horbol- M ystrate- A cetate (about - 20 % of the base stimulation) [fig. 5].
  • memantine almost completely inhibits the base stimulation of all stimulating agents at a concentration of 10 -3 .
  • the regulative effect of the aminoadamantane compounds according to the invention is highly specific for neutrophils.
  • the aminoadamantane compounds do not show any action on the deregulation effect of activated leukocytes.
  • ACC (1-aminocyclopropane-1-carboxylic acid) itself does not react with memantine in relatively high concentrations.
  • ACC is a specific indicator for myeloperoxidase which is released by degranulation of leukocytes and forms damaging hypochlorite in extracellular spaces.
  • Myeloperoxidase reacts specifically with ACC under formation of ethylene which can be detected gaschromatographically. Therewith, the formed amount of ethylene represents an indirect measuring quantity for leukocyte activity.
  • the indicator for the respiratory burst and the oxygen radicals arising therefrom are activated by memantine. This is already shown at a concentration of only 10 -7 M which can easily be obtained in vivo.
  • the activation effect can be made visible by addition of Fe 3+ which shifts the equilibrium of the reaction through the Haber-Wêt reaction from superoxide and hydrogenperoxide to the direction of OH radicals.
  • a sensitive indicator for oxygen species of this type is KMB (a-keto-g-methylthiobutyrate) which disintegrates into ethylene, among others, under oxidative conditions and which can be easily detected [fig. 7].
  • fig. 8 shows that the KMB-reaction, but not the ACC-reaction, is stimulated first by the addition of Fe 3+ at the concentration of > 5x10 -4 M. Fe 3+ alone is without influence.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP02026914A 1995-08-25 1996-08-21 Utilisation de composés d'aminoadamantane en tant qu'immunorégulateurs Withdrawn EP1293201A3 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19531342A DE19531342B4 (de) 1995-08-25 1995-08-25 Verwendung von Aminoadamantan-Verbindungen als Immunregulatoren
DE19531342 1995-08-25
EP96930065A EP0845984B1 (fr) 1995-08-25 1996-08-21 Utilisation de composes d'aminoadamantane en tant qu'immunoregulateurs

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP96930065A Division EP0845984B1 (fr) 1995-08-25 1996-08-21 Utilisation de composes d'aminoadamantane en tant qu'immunoregulateurs

Publications (2)

Publication Number Publication Date
EP1293201A2 true EP1293201A2 (fr) 2003-03-19
EP1293201A3 EP1293201A3 (fr) 2003-05-21

Family

ID=7770407

Family Applications (2)

Application Number Title Priority Date Filing Date
EP02026914A Withdrawn EP1293201A3 (fr) 1995-08-25 1996-08-21 Utilisation de composés d'aminoadamantane en tant qu'immunorégulateurs
EP96930065A Expired - Lifetime EP0845984B1 (fr) 1995-08-25 1996-08-21 Utilisation de composes d'aminoadamantane en tant qu'immunoregulateurs

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP96930065A Expired - Lifetime EP0845984B1 (fr) 1995-08-25 1996-08-21 Utilisation de composes d'aminoadamantane en tant qu'immunoregulateurs

Country Status (21)

Country Link
US (2) US6172116B1 (fr)
EP (2) EP1293201A3 (fr)
JP (1) JPH11512093A (fr)
KR (1) KR100392986B1 (fr)
CN (1) CN1282452C (fr)
AT (1) ATE234083T1 (fr)
AU (1) AU718219B2 (fr)
CA (1) CA2230159C (fr)
CZ (1) CZ299356B6 (fr)
DE (3) DE19531342B4 (fr)
DK (1) DK0845984T3 (fr)
EE (1) EE04261B1 (fr)
ES (1) ES2193259T3 (fr)
GE (1) GEP19991779B (fr)
IL (1) IL123394A (fr)
MX (1) MX217078B (fr)
NO (1) NO319153B1 (fr)
RU (1) RU2219916C2 (fr)
UA (1) UA57711C2 (fr)
WO (1) WO1997007791A1 (fr)
ZA (1) ZA967137B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL146143A0 (en) * 1999-04-28 2002-07-25 Univ Kingston Compositions and methods for treating amyloidosis
RU2196575C2 (ru) * 1999-07-30 2003-01-20 Научно-исследовательский институт фармакологии РАМН Вещество, обладающее психостимулирующим и антиастеническим действием
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
RU2226391C2 (ru) * 2002-05-28 2004-04-10 Плотников Владимир Михайлович Средство для повышения активности нейтрофилов
RU2246482C2 (ru) * 2002-12-25 2005-02-20 ООО "Циклан" Способ получения гидрохлорида 1-амино-3,5-диметиладамантана
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
WO2006011823A1 (fr) * 2004-06-24 2006-02-02 Akciju Sabiedriba 'olainfarm' Agent immunostimulateur et interférogène
BRPI0519243A2 (pt) 2004-12-22 2009-01-06 Neurochem Int Ltd mÉtodos e composiÇÕes para tratar doenÇas relacionadas a amilàide
DK2089417T3 (en) 2006-10-12 2015-03-23 Bhi Ltd Partnership Methods, Compounds, Compositions and Vehicles for Delivery of 3-Amion-1-Propanesulfonic Acid
EP2604591A4 (fr) * 2010-08-09 2015-07-22 Shionogi & Co Procédé pour préparer des dérivés d'aminoadamantyl carbamate
WO2017223402A1 (fr) 2016-06-23 2017-12-28 Corium International, Inc. Matrice adhésive à un domaine hydrophile, un domaine hydrophobes et un agent thérapeutique
CN116270551A (zh) 2016-07-27 2023-06-23 考里安有限责任公司 通过盐至中性药物原位转化的组合物、透皮贴剂及应用
WO2018022814A1 (fr) 2016-07-27 2018-02-01 Corium International, Inc. Systèmes d'administration transdermique à pharmacocinétique bioéquivalent à l'administration orale
EP3490544A1 (fr) 2016-07-27 2019-06-05 Corium International, Inc. Systèmes d'administration transdermique de mémantine
US11173132B2 (en) 2017-12-20 2021-11-16 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3450761A (en) * 1967-03-30 1969-06-17 Sun Oil Co 1-aminoethyldimethyladamantane
DE4014672A1 (de) * 1990-05-08 1991-11-14 Werner E G Prof Dr Mueller Verwendung von adamantan-derivaten zur zytoprotektion von nicht-infizierten und virus-infizierten lymphozyten als auch anderen zelltypen

Also Published As

Publication number Publication date
CA2230159A1 (fr) 1997-03-06
CA2230159C (fr) 2008-02-26
EE04261B1 (et) 2004-04-15
NO980793L (no) 1998-02-25
WO1997007791A1 (fr) 1997-03-06
DE10399029I1 (de) 2004-01-08
NO319153B1 (no) 2005-06-27
US6255348B1 (en) 2001-07-03
CZ52498A3 (cs) 1999-04-14
IL123394A0 (en) 1998-09-24
ZA967137B (en) 1997-03-12
KR100392986B1 (ko) 2003-11-17
US6172116B1 (en) 2001-01-09
CN1198669A (zh) 1998-11-11
DE69626650D1 (de) 2003-04-17
EP1293201A3 (fr) 2003-05-21
UA57711C2 (uk) 2003-07-15
ES2193259T3 (es) 2003-11-01
DE69626650T2 (de) 2003-12-18
RU2219916C2 (ru) 2003-12-27
NO980793D0 (no) 1998-02-25
EE9800057A (et) 1998-08-17
CZ299356B6 (cs) 2008-07-02
EP0845984B1 (fr) 2003-03-12
CN1282452C (zh) 2006-11-01
DE19531342A1 (de) 1997-02-27
ATE234083T1 (de) 2003-03-15
MX9801496A (es) 1998-05-31
AU6926396A (en) 1997-03-19
GEP19991779B (en) 1999-10-05
DK0845984T3 (da) 2003-06-23
IL123394A (en) 2004-07-25
AU718219B2 (en) 2000-04-13
JPH11512093A (ja) 1999-10-19
MX217078B (es) 2003-10-22
KR19990044096A (ko) 1999-06-25
EP0845984A1 (fr) 1998-06-10
DE19531342B4 (de) 2007-11-29

Similar Documents

Publication Publication Date Title
US6172116B1 (en) Use of aminoadamantane compounds as immunoregulators
Kis et al. Diazoxide induces delayed pre‐conditioning in cultured rat cortical neurons
Leopold et al. Anticancer activity of the structurally novel antibiotic CI-920 and its analogues
EP1552745B1 (fr) Composées thérapeutiques contenant des dilateurs veineux et des dilateurs arteriels
JPH05504936A (ja) アイコサペンタエノン酸の悪液質治療への利用
Chen et al. Inhibition of angiotensin-I-converting enzyme by tetrahydroxyxanthones isolated from Tripterospermum lanceolatum
WO2019002542A1 (fr) Combinaison d'un inhibiteur de mps1 et d'un composé de taxane, ses utilisations et compositions pharmaceutiques la comprenant
EP1218011B1 (fr) Complexes de gallium de 3-hydroxy-4-pyrones destines au traitement d'infections par des procaryotes intracellulaires, des virus a adn et des retrovirus
KR0143410B1 (ko) B형 비루스성 간염치료용 제약학적 조성물
CA2055041A1 (fr) Utilisation de xanthines pour la preparation d'un medicament assurant une inhibition efficace de la replication des retrovirus humains
HK1051496A (en) Use of aminoadamantane compounds as immunoregulators
US6476009B1 (en) Method for control and treatment of acquired immunodeficiency syndrome (AIDS)
WO1991002810A1 (fr) Agents d'oxydation de nmda protegeant les neurones contre les lesions
JPS5849315A (ja) 抗腫瘍剤
HU224984B1 (en) Use of aminoadamantane compounds as immunoregulators
WO2022128810A1 (fr) Matériels et méthodes pour le traitement de pathologies virales et autres pathologies médicales
EP0728002B1 (fr) Utilisation de derives de 2-aminopurine dans le traitement et la prophylaxie des infections par l'herpesvirus 7 humain
KR0124028B1 (ko) 후천성 면역 결핍증의 예방 및 치료제
US11986507B1 (en) Micronutrient composition to improve men's health
ES2211949T3 (es) Uso de penciclovir para el tratamiento del herpesvirus humano 8.
WO1992000734A1 (fr) Traitement d'une infection microbienne a l'aide de medicaments contenant de l'acide para-acetamidobenzoique
Cherrick et al. Effect of ibuprofen on the in vitro and in vivo reactivation of latent HSV-1
Taher Herbimycin A inhibits protein kinase C in vascular smooth muscle cells
WO2023037173A1 (fr) Composition pharmaceutique de micronutriments à utiliser pour améliorer simultanément la fonction du système nerveux, la capacité cognitive et la réponse à des facteurs de stress
FR2726186A1 (fr) Medicaments contenant des inhibiteurs de la nitrique-oxyde synthase

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 0845984

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: LT LV

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: LT LV

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/13 A

17P Request for examination filed

Effective date: 20031006

AKX Designation fees paid

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20041227

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050509

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1051496

Country of ref document: HK